630 Shares in argenex SE $ARGX Bought by PSP Research LLC

PSP Research LLC bought a new stake in shares of argenex SE (NASDAQ:ARGX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 630 shares of the company’s stock, valued at approximately $530,000.

Several other institutional investors have also recently added to or reduced their stakes in ARGX. M&T Bank Corp lifted its holdings in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP lifted its holdings in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Two Sigma Investments LP lifted its holdings in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the period. Woodline Partners LP lifted its holdings in argenex by 320.8% in the 3rd quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock valued at $124,999,000 after acquiring an additional 129,205 shares during the last quarter. Finally, Alkeon Capital Management LLC lifted its holdings in argenex by 133.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 175,000 shares of the company’s stock valued at $129,073,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Trading Up 2.8%

ARGX opened at $797.77 on Wednesday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The stock has a market capitalization of $49.37 billion, a price-to-earnings ratio of 35.52, a P/E/G ratio of 1.24 and a beta of 0.46. The business has a 50 day moving average of $762.86 and a 200-day moving average of $816.06.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. Equities analysts predict that argenex SE will post 25.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ARGX. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Wells Fargo & Company upped their target price on argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. HC Wainwright boosted their price target on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Glj Research raised argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.